AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
Rhea-AI Summary
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin complex treatments, has announced its participation in the upcoming Aegis Capital Corp. 2025 Virtual Conference. The company's President and CEO, Rob Bancroft, will deliver a corporate overview presentation on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. AEON's focus is on developing treatments for multiple therapeutic indications using their botulinum toxin complex technology.
Positive
- None.
Negative
- None.
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON’s President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET.
Please register here to attend the conference on Wednesday, May 21st.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
When is AEON Biopharma (AEON) presenting at the Aegis Capital Corp. Virtual Conference 2025?
Who will be presenting for AEON Biopharma at the Aegis Conference 2025?
What is AEON Biopharma's (AEON) main focus as a company?
What stock exchange is AEON Biopharma listed on?
